SeaBeLife: SeaBeLife Reports Promising In Vivo Results for it Ophthalmic Gel Candidate for GA
SeaBeLife announced in vivo results for its SBL03 drug candidate, an ophthalmic gel designed to combat necrotic retinal cell death in g
Read full article »
SeaBeLife is a France-based biotechnology company that researches and develops small molecules for the treatment of regulated necrosis.
Read more